Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 1

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 1
---
 growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement. On June 2, 2025, TuHURA Biosciences, Inc. (the “Company”) and investors (the “Purchasers”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to issue to the Purchasers, in a private placement (the “Offering”), an aggregate of 4.76 million shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), together with warrants to purchase an equal number of shares of Common Stock at an exercise price of $3.3125 (the “Warrants”), for an aggregate offering amount of approximately $12.6 million. The combined effective offering price for each Share and accompanying Warrant in the Offering was $2.65. Pursuant to the Securities Purchase Agreement, each Purchaser will be obligated to purchase such Purchaser’s respective investment in the Offering in four equal tranches, as follows:

| • |     | $2.23 million at the initial closing date immediately after the execution of the Securities Purchase 
 Agreement (the “Initial Closing”);                                                                   |

| • |     | $2.23 million will be purchased on the third business day after the date on which the Company notifies the                                                                                                                                    
 Purchasers that the Food and Drug Administration (FDA) has notified the Company that the Company is no longer subject to the partial clinical hold set forth in the FDA’s Partial Clinical Hold letter to the Company dated January 24, 2024, 
 with respect to the Company’s planned Phase 3 trial of IFx-2.0;                                                                                                                                                                               |

| • |     | $2.23 million will be purchased on the third business day after the date on which the Company notifies the 
 Purchasers that the Phase 3 trial for IFx-Hu2.0 (the “Phase 3 Trial”) has been initiated; and              |

| • |     | $2.23 million will be purchased on the third business day after the date on which the Company notifies the                                                                                                                               
 Purchasers that all material conditions for the closing of the Company’s proposed merger transaction with Kineta, Inc. (the “Kineta Merger